1. Cholangiocarcinoma The Lancet
Nataliya Razumilava, MD, Prof Gregory J Gores, MD 
The Lancet 
Volume 383, Issue 9935, Pages (June 2014)
DOI: /S (13)
Copyright © 2014 Elsevier Ltd Terms and Conditions

2. Figure 1
Integrative approach to (A) diagnosis and (B) individualised medicine in cholangiocarcinoma
FISH=fluorescence in-situ hybridisation. SDS-PAGE=sodium dodecyl sulfate polyacrylamide gel electrophoresis.
The Lancet  , DOI: ( /S (13) )
Copyright © 2014 Elsevier Ltd Terms and Conditions

3. Figure 2 Potential cells of origin in intrahepatic cholangiocarcinoma
PV=portal vein. HA=hepatic artery. BD=bile duct. HC=hepatic cell.
The Lancet  , DOI: ( /S (13) )
Copyright © 2014 Elsevier Ltd Terms and Conditions

4. Figure 3
Approach to management of (A) intrahepatic and (B) perihilar cholangiocarcinoma
HCC=hepatocellular carcinoma. CA 19-9=carbohydrate antigen Reproduced with modifications from reference 69 by permission of Elsevier.
The Lancet  , DOI: ( /S (13) )
Copyright © 2014 Elsevier Ltd Terms and Conditions

5. Figure 4
Imaging studies of a patient with perihilar cholangiocarcinoma of the left hepatic duct
Note prominent left hepatic duct dilatation with obstruction of the left hepatic duct system on the CT scan (A), MRI (B), endoscopic retrograde cholangiography (C), and magnetic resonance cholangiography (D); (D) also shows bilateral obstruction of the biliary system at the right and left hepatic bile duct confluence.
The Lancet  , DOI: ( /S (13) )
Copyright © 2014 Elsevier Ltd Terms and Conditions